INTRODUCTION
FOLFOX and FOLFIRI are standard regimen for metastatic colorectal cancer (mCRC) (1 -4) . The addition of bevacizumab to standard chemotherapy improved progression-free survival in patients with mCRC (5 -7). Chemotherapyinduced interstitial lung disease (ILD) in CRC patients treated with bevacizumab is rare (8, 9) , and the clinical features of these patients are unclear. We experienced four rare cases with ILD during standard chemotherapy combined with bevacizumab. We herein reported the clinical features of these patients.
PATIENTS AND METHODS
The medical records for a series of consecutive patients with CRC treated with standard chemotherapy combined with bevacizumab at the Division of Surgery, NTT Medical Center Tokyo, between December 2008 and November 2010 were retrospectively reviewed. The electronic medical records of these patients were reviewed to obtain clinical and demographic data, including gender, age, smoking history, primary site of CRC, treatment, treatment-related toxicities and survival. Pulmonary toxicities related to treatment were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0). Members of the Division of Respirology, made up of experts from pulmonary medicine (K.U., Y.T., C.T. and T.I.) and oncology (C.T.), diagnosed ILD according to the diagnostic algorithm of gefitinib-associated ILD in Japanese patients with non-small cell lung cancer (NSCLC) (10) and subclassified the ILD pattern according to the ATS guidelines (11) . Briefly, patients were diagnosed as having ILD if the following criteria were met: (1) acute onset or exacerbation of interstitial shadows on chest computed tomography (CT); (2) antibiotics did not improve symptoms and radiological findings; (3) exclusion of other possible causes of (1), especially cardiac failure and progression of cancer. The study protocol was reviewed and approved by Ethics Committee of the NTT Medical Center, Tokyo.
RESULTS

PATIENT CHARACTERISTICS BEFORE CHEMOTHERAPY
We reviewed 104 patients with CRC treated with standard chemotherapy combined with bevacizumab. Characteristics of patients treated with chemotherapy combined with bevacizumab are shown in Table 1 . Of the 104 patients, 101 received FOLFOX, 61 received FOLFIRI and 14 received XELOX. We identified ILD occurrence in four patients (3.85%). All patients who developed ILD were diagnosed and treated at the Division of Respirology, NTT Medical Center Tokyo. Characteristics of patients with ILD during standard chemotherapy combined with bevacizumab are shown in Table 2 . The median age was 64.5 years (range 56 -72). All patients were men, and three of four patients had a history of heavy smoking. The primary site of CRC was the rectum in two patients and the sigmoid colon in two patients. The primary cancer was resected in all four patients. The pulmonary function test examined in two patients showed normal values. Chest CT examined before chemotherapy showed fibrosis in one patient (Case 4, Fig. 1A ) and emphysema in one patient. All patients did not have respiratory symptoms before chemotherapy. Ex, ex-smoker; PS, performance status; FOLFOX, 5-fluorouracil (5FU) þ levofolinate þ oxaliplatin; FOLFIRI, 5FU þ levofolinate þ irinotecan; XELOX, capecitabine þ oxaliplatin. Jpn J Clin Oncol 2011;41(4) 499
CLINICAL COURSE OF ILD
The clinical course of ILD has been summarized in Table 3 . ILD developed during chemotherapy with FOLFOX þ bevacizumab in two patients and during chemotherapy with FOLFIRI þ bevacizumab in two patients. All ILD patients had received FOLFOX. The median number of oxaliplatincontaining therapy was 10 (range 9 -15 cycles). The initial symptom of ILD was fever in all patients. The median duration from the last chemotherapy to the onset of ILD was 3.5 days (range 2 -8). The grade of ILD according to the CTCAE v3.0 was Grade 2 in one patient, Grade 3 in two patients and Grade 4 in one patient. KL-6, a marker associated with pulmonary alveolar damage, was within normal range except in one patient (Case 1: 618 U/ml; normal range: ,500 U/ml).
CHEST CT FINDINGS OF ILD
Chest CT at ILD showed bilateral distribution in all four patients, ground-glass opacities in all four patients, consolidation in three patients, pleural effusion in one patient (Case 2, Fig. 2 ) and honeycomb in one patient (Case 4, Fig. 1B ). According to the ATS guideline (11), one patient showed an acute interstitial pneumonia pattern, one showed an idiopathic pulmonary fibrosis pattern and two showed an organizing pneumonia pattern.
TREATMENT OF ILD AND OUTCOME Sputum culture of bacteria and fungus was negative in all patients with ILD. Beta D-glucan was within the normal range in all patients. Viral infection was not examined in all patients. Empirical administration of antibiotics was not effective in all patients. We treated three patients with a high-dose steroid [methylpredonisolone (mPSL) 1 g/day for 3 days] followed by prednisolone and one patient with preexisting pulmonary fibrosis (Case 4) with a high-dose steroid followed by prednisolone with cyclosporin A (CsA). The median length of hospital stay was 13 days (range 8 -67 days). All patients improved with steroid therapy.
CHEMOTHERAPY AFTER ILD OCCURRENCE
Two patients received chemotherapy after ILD improved. One patient (Case 1) received XELOX þ bevacizumab 1 month later after the ILD occurrence. At day 21 of XELOX þ bevacizumab, he complained of fever. Chest radiograph showed infiltration at the right upper lung (Fig. 3) . Although we treated him with antibiotics, his symptoms did not disappear. The patient received steroid therapy and his symptoms rapidly improved. We diagnosed him with ILD recurrence induced by XELOX þ bevacizumab. Two patients received anti-epidermal growth factor receptor (EGFR) antibody; one (Case 1) received cetuximab and one (Case 3) received panitumumab. No ILD recurrence was observed in these patients during anti-EGFR antibody treatment.
DISCUSSION
We experienced ILD in four patients with CRC during standard chemotherapy combined with bevacizumab. Although ILD in this study rapidly progressed and were severe, all patients responded well to high-dose steroid therapy and survived.
We showed that ILD was noted in 4 of 104 (3.9%) patients with advanced CRC who received bevacizumab combined with standard chemotherapy including FOLFOX (n ¼ 101), FOLFIRI (n ¼ 61) and XELOX (n ¼ 14). This incidence seems higher than those of the previous reports Shimura et al. reported that of 734 patients treated with FOLFOX or FOLFIRI, 11 patients developed ILD (1.5%) and 4 of those patients died (0.54%) (8) . They showed that FOLFOX and oxaliplatin have a great effect on ILD onset in patients. Japanese post-marketing surveillance of irinotecan for 15 385 patients showed that the incidence of ILD induced by irinotecan was 0.9% in patients with CRC. Serious hemoptysis was encountered in patients with NSCLC during bevacizumab treatment (12) ; however, such pulmonary toxicities have not been reported in patients with CRC (13). Post-marketing large cohort study of bevacizumab safety in Japanese CRC patients from June to December 2007 showed that the incidence rate of ILD was 0.16%. Retrospective analysis of the adverse-event reports from patients diagnosed with ILD during chemotherapy is difficult as there is often limited or heterogeneous clinical information, no pathology result and no access to the results of radiological investigations (14) . Although we diagnosed ILD in this study without bronchoalveolar lavage and transbronchial biopsy, we diagnosed ILD according to the algorithm using both radiological and clinical evidence to exclude alternative diagnoses, such as infection, tumor progression and heart failure. This approach aids early and accurate diagnosis of drug-associated ILD in clinical practice (12, 14) . High incidence of ILD in this study 
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ILD in CRC treated with bevacizumab might be partly explained by the diagnostic procedure using this algorithm. Although ILD developed in two patients during chemotherapy with FOLFOX þ bevacizumab and in two patients during chemotherapy with FOLFIRI þ bevacizumab, all ILD patients had received a median of 10 cycles of FOLFOX before the onset of ILD. A median of 10 cycles of oxaliplatin had been administered in the previous study (8) . One patient (Case 1) who subsequently received an oxaliplatin-based regimen (XELOX þ bevacizumab) developed ILD recurrence. It is difficult to identify the causative drug of ILD in this study, however, oxaliplatin has a great impact on the onset of ILD in Case 1 as described by Shimura et al. (8) . Changes in vascular endothelial growth factor (VEGF) expression play a significant role in the pathophysiology of acute lung injury (15 -17) . Low levels of VEGF have been found in the lungs of patients with early adult respiratory distress syndrome (ARDS) (15,16) and increasing intrapulmonary VEGF levels are associated with resolution of lung injury in ARDS (17) . Bevacizumab is an IgG1 recombinant humanized monoclonal antibody to VEGF that blocks binding of human VEGF to its receptors. Although the association of VEGF with ILD induced by chemotherapy is not clear, the blockage of VEGF by bevacizumab may influence the lung injury induced by cytotoxic drugs. Further investigation is necessary to elucidate whether the addition of bevacizumab to standard chemotherapy increases the pulmonary toxicities.
The risk factors of ILD during chemotherapy in patients with CRC are not clear. Kudoh et al. (10) reported that ILD induced and/or exacerbated by drugs was relatively common in Japanese patients with NSCLC during chemotherapy and that ILD-related death in patients with ILD occurred in 30% of the subjects. They showed that risk factors for ILD are older age, poor World Health Organization performance status, reduced normal lung area on CT scans, preexisting There were no firm guidelines for the treatment of drug-associated ILD (14) . All patients in this study received high-dose mPSL (1 g/day for 3 days) on an empirical basis. All patients responded well to steroid therapy. After highdose mPSL therapy, three patients received predonisolone alone and one patient with preexisting pulmonary fibrosis (Case 4) received CsA combined with steroid. Although corticosteroid (CS) has been utilized for treating acute exacerbation of pulmonary fibrosis, the effectiveness of CS is limited (18 -20) . Several reports have shown that CsA is efficacious (21 -23) , and the Japanese Respiratory Society recommended that steroid therapy combined with immunosuppressants, including CsA, azathioprine or cyclophosphamide, is one of the alternative treatments for the acute exacerbation of pulmonary fibrosis (18) . Because we could not differentiate whether ILD in Case 4 was an acute exacerbation of preexisting pulmonary fibrosis or associated with chemotherapy, we treated him with CsA following the treatment of acute exacerbation of pulmonary fibrosis.
We experienced four (3.8%) ILD patients with CRC during standard chemotherapy combined with oxaliplatin and/or bevacizumab. ILD during chemotherapy including bevacizumab was rare, but rapidly progressed and was severe. High-dose steroid therapy was effective for the ILD during chemotherapy with FOLFOX or FOLFIRI and bevacizumab in our experience.
